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PODIUM SESSION I: CARDIOVASCULAR DISEASE I
CV1
POST-AMI DRUGTHERAPY PERSISTENCE AND RISK OF
REINFARCTION IN A MEDICAID POPULATION
Shaya FT, Gu A
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: To assess the effect of persistence on statin,
a-blocker, or Calcium Channel Blocker (CCB) therapy, on the
risk of reinfarction in a Medicaid high-risk, largely female,
predominantly minority population. METHODS: Prospective
nonconcurrent cohort, longitudinal data analysis of medical
and pharmacy claims of Acute Myocardial Infarction (AMI)
Medicaid MCO patients, observed between January 1, 2002 and
December 31, 2004. Cox proportional hazards models were used
to predict the likelihood of a reinfarction as a function of persis-
tence on the ﬁrst medication post-AMI, adjusting for age, race,
sex, heart disease and other comorbidities, and other medica-
tions. RESULTS: Among 515 AMI patients (58% female and
54% African American), hypertension (91%) and heart disease
(81%) were the most prevalent comorbidities; most initial AMIs
were non-transmural. Discontinuation of statin, a-blocker,
or CCB post-AMI increased the likelihood of a reinfarction
(HR = 1.66; 95% CI 1.03–2.69). Concurrent heart disease,
hyperlipidemia, or renal disease signiﬁcantly increased the like-
lihood of a reinfarction. Age, race and sex did not signiﬁcantly
predict the likelihood of reinfarction. CONCLUSION: Persis-
tence on the ﬁrst post-AMI preventive medication is effective at
avoiding a reinfarction. Concomitant heart disease, renal disease
and hyperlipidemia increases the likelihood of a reinfarction.
CV2
COST-EFFECTIVENESS OF ROSUVASTATINVERSUS
ATORVASTATIN, SIMVASTATIN,AND PRAVASTATIN FROM A
CANADIAN HEALTH CARE PERSPECTIVE
Costa-Scharplatz M1, Beamer B2, Frial T2, Gandhi SK3
1AstraZeneca, Södertälje, Sweden, 2AstraZeneca, Mississauga, ON,
Canada, 3AstraZeneca, LP,Wilmington, DE, USA
OBJECTIVES: To estimate cost-effectiveness of rosuvasta-
tin (RSV) versus atorvastatin (ATV); simvastatin (SMV), and
pravastatin (PRV) in managing lipid proﬁle parameters from
a Canadian system perspective. METHODS: Annual cost-
effectiveness ratios of RSV, ATV, SMV, and PRV were estimated
in patients with hypercholesterolemia in terms of cost per percent
LDL-C and TC/HDL-C and ApoB/ApoA-I reductions and
Canadian guideline LDL-C goal attainment. Efﬁcacy data were
from a randomized, open-label trial including 2,268 adults
(Jones et al, 2004). Drug costs [Can$, branded ATV and RSV;
generic (g) SMV and gPRV] and dose utilization pattern within
each statin from the Canadian province of British Columbia
(March 2007) were used. Probabilistic sensitivity analysis was
performed. RESULTS: RSV10 had lowest annual cost per
percent reduction in LDL-C ($10.79), TC/HDL ($13.29) and
ApoB/ApoA-I ($12.11), followed by gSMV80 ($11.19, $14.00,
$13.20). After aggregating statin doses based on utilization
pattern, RSV provided lowest mean annual cost per percent
reduction in LDL-C ($11.03), TC/HDL ($13.55) and ApoB/
ApoA-I ($12.39), followed by gSMV ($14.04, $16.96, $15.90),
ATV ($16.93, $20.81, $19.48) and gPRV ($16.98, $20.01,
$17.84), respectively. Cost per patient at goal was lowest for RSV
($603.46) followed by gPRV ($687.23), gSMV ($719.67) and
ATV ($934.12). RSV was more effective and less costly than ATV
on all assessed effectiveness measures. Comparing rosuvastatin to
gSMV and gPRV, the value of an additional one percent reduc-
tion in LDL-C was $2.11 and $3.99, TC/HDL was $2.72 and
$5.17, ApoB/ApoA-I was $2.30 and $4.88, and per one addi-
tional patient to goal was $143.64 and $373.91, respectively.
Cost-effectiveness acceptability curve showed that RSV was the
most cost-effective statin over a broad range of “willingness-to-
pay” values per unit of clinical effect. CONCLUSION: Irrespec-
tive of effectiveness measure chosen, rosuvastatin can be
considered as most cost-effective statin compared with ator-
vastatin, generic simvastatin and generic pravastatin in the
Canadian province of British Columbia.
CV3
DO DIFFERENCES IN DOSE IMPACT ADHERENCETO
SINGLE-PILL AMLODIPINE/ATORVASTATINVERSUS 2-PILL
AMLODIPINE AND ATORVASTATIN?
Tang SSK1, Patel BV2, Leslie RS2,Thiebaud P2, Nichol MB3,
Solomon HA1,Trainer JB1, Foody JM4
1Pﬁzer Inc, New York, NY, USA, 2MedImpact Healthcare Systems, Inc,
San Diego, CA, USA, 3University of Southern California, Los Angeles,
CA, USA, 4Yale University, New Haven, CT, USA
OBJECTIVES: To determine whether single-pill amlodipine
besylate/atorvastatin calcium (SPAA) use achieved greater adher-
ence vs. 2-pill amlodipine besylate and atorvastatin calcium
(2PAA), at low, high, and European doses. METHODS: This
study assessed drug beneﬁts managed by a large U.S. Pharmacy
Beneﬁt Management company. Patients newly initiated on either
a CCB or a statin within 30 days of each other were followed-up
for 6 months. Sub-analyses were conducted with patients on
SPAA (N = 795) and 2PAA (N = 735), and both groups were
stratiﬁed based on dose; SPAA vs 2PAA comparisons were made
for low-dose (2.5, 5 mg) and high-dose (10 mg) amlodipine,
low-dose (10 mg) and high-dose (20, 40, 80 mg) atorvastatin,
and the European doses of SPAA (5/10 mg, 10/10 mg). Adher-
ence was measured as proportion of days covered (PDC) based
on the days that both amlodipine and atorvastatin were supplied
over 6 months. Adherence was considered achieved if PDC was
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80%. Persistence was deﬁned as the number of days on thera-
pies until the ﬁrst 30-day gap. Propensity-score weighted logistic
regression and proportional hazard models were used to adjust
for baseline demographics, copay and pharmacy utilization vari-
ables. RESULTS: At baseline, across the SPAA and 2PAA groups
(N = 1,530), mean age was 62 years, 49% were female, 10%
utilized coronary vasodilators, 28% utilized anti-diabetics; mean
number of other baseline medications was 7. These characteris-
tics varied among all cohorts. Patients receiving SPAA were
nearly twice as likely to achieve adherence, and approximately
20% less likely to discontinue therapy at all doses; compared to
the European dose equivalents, the adjusted odds ratio of achiev-
ing adherence was 1.83 (95% conﬁdence interval (CI) 1.60–2.10,
P < 0.0001) and the discontinuation hazard ratio was 0.83 (CI
0.74–0.93, P = 0.0012). CONCLUSION: Single-pill amlodipine/
atorvastatin was associated with greater adherence and less dis-
continuation vs. 2-pill amlodipine and atorvastatin, at low, high,
and European doses of both medications.
CV4
BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS
FIRST-LINETREATMENT OF SEVERE HYPERTENSION
Lapuerta P1, Gomez A2, Franklin S3
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb,
Hopewell, NJ, USA, 3University of California at Irvine, Los Angeles,
CA, USA
OBJECTIVES: Although guidelines recommend ﬁrst-line combi-
nation therapy for patients with severe hypertension, no quanti-
tative beneﬁt/risk estimate has been provided. The objective of
this study was to estimate these potential long-term beneﬁts and
risks based on results of a registrational clinical program.
METHODS: Results from a clinical study in severe hypertension
(diastolic blood pressure > = 110 mmHg) were used to project
beneﬁts and risks of irbesartan/hydrochlorothiazide (I/H) vs.
irbesartan monotherapy (I). In the randomized, controlled,
double-blind, 7-week trial (n = 695), initial I/H reduced exposure
to severe blood pressure (BP) levels (p = 0.0003) and provided an
additional BP reduction of approximately 10/5 mmHg (systolic/
diastolic) compared to I (p < 0.0001 for each parameter) with
similar safety. Beneﬁt was extrapolated by using cardiovascular
risks described in World Health Organization Guidelines. The BP
difference between I/H and I was applied conservatively to a time
frame of 0.1 to 0.8 years, as physicians in actual practice may
add adjunctive therapy after the initial prescription. The poten-
tial for serious adverse events from the use of I/H were estimated
based on post-marketing surveillance data (10 million patient
years of exposure to I/H) and literature review. RESULTS: A
population of 100,000 patients with severe hypertension is at
risk for between 2,500 and 10,000 cardiovascular events in one
year. Initial treatment with I/H instead of I is projected to prevent
between 100 and 1,000 events in one year. No signal of poten-
tially serious adverse events exists for I/H compared to I in
post-marketing data, but an estimate of between 0 to 3 such
events may be considered. CONCLUSION: The estimated
beneﬁt/risk of ﬁrst-line I/H is highly favorable, even when applied
to a short time horizon. This is because cardiovascular risk is the
greatest issue for the patient with severe hypertension. Earlier
and more extensive use of combination therapy can improve
public health.
PODIUM SESSION I: ECONOMICS OF DIABETES
ED1
COST-EFFECTIVENESS OF INSULIN DETEMIRVERSUS NPH
FORTYPE 1 DIABETES PATIENTS IN A GERMAN SETTING.
A MODELING EVALUATION BASED UPON RESULTS FROM
A META-ANALYSIS
Kotchie R1, Scheijbeler H1,Aagren M2, Nielsen S2,Valentine WJ3,
Goodall G3
1IMS Health, London, UK, 2Novo Nordisk A/S,Virum, Denmark,
3IMS Health, Basel, Switzerland
OBJECTIVES: A ﬁxed-effects (weighted average) meta-analysis
of three clinical trials showed the short-term therapy beneﬁts of
treating type 1 diabetic patients (mean age 40.3 years, duration
of diabetes 16.3 years, HbA1c 8.3%, BMI 25.2 kg.m-2) with
insulin detemir (IDet) versus neutral protamine Hagedorn (NPH)
insulin as the basal component of basal-bolus therapy when used
in combination with either insulin aspart (IAsp) or human
soluble insulin (HSI). METHODS: A published validated diabe-
tes model was used to estimate the long-term cumulative inci-
dence of complications, life expectancy (LE), quality-adjusted life
expectancy (QALE) and lifetime costs for IDet versus NPH regi-
mens. The short-term treatment effects (0.13% points lower
HbA1c, a 4% decrease in hypoglycaemic events and lower body
mass index 0.21 kg.m-2) observed in the meta-analyses were
projected using progression data derived from landmark clinical
and epidemiological studies. The costs of treating complications
in the German setting were taken from published sources and
total direct costs (complications + treatment costs) for each arm
were projected over patient lifetimes. Both costs and clinical
outcomes were discounted at 5% annually. RESULTS: The IDet
arm was associated with an increase in life expectancy, compared
to NPH, of 0.052 years (12.270  0.130 versus 12.218  0.121
years) with a resulting gain in QALE of 0.144 quality-adjusted
life years (QALYs) (6.23  0.07 versus 6.09  0.06 QALYs)
due to a reduction in diabetes-related complications. Increased
treatment costs for IDet resulted in greater total lifetime
costs per patient than with NPH (€91,960  2333 versus
€89,367  2183, difference €2,593), leading to an incremental
cost-effectiveness ratio of €18,070 per QALY gained. CONCLU-
SION: Short-term improvements seen with IDet versus NPH in
basal-bolus therapy were projected to show improvements in
both life expectancy and quality-adjusted life expectancy with a
cost-effectiveness ratio which fell well within the range usually
considered to represent value for money (<€50,000 per QALY
gained).
ED2
LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART
(NOVORAPID®)VERSUS HUMAN SOLUBLE INSULIN INTYPE
2 DIABETES PATIENTS INTHE GERMAN SETTING
Goodall G1,Valentine WJ1,Townsend C2, Kotchie R3, Nielsen S2,
Erny-Albrecht K1
1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S,Virum, Denmark,
3IMS Health, London, UK
OBJECTIVES: The aim of this analysis was to evaluate the
cost-utility of switching type 2 diabetes patients receiving human
soluble insulin (HSI) to rapid-acting insulin aspart (IAsp,
NovoRapid), with or without oral hypoglycemic agents, in the
German setting. METHODS: The CORE Diabetes Model, a
published and validated computer simulation model, was used to
project long-term clinical and economic outcomes associated
with IAsp and HSI treatment effects. The model is based on 15
semi-Markov sub-models representing the most important acute
and chronic diabetes-related complications including eye, renal
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